NCT05866614 - A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps | Biotech Hunter

Enrollment

864

Participants

Timeline

Start Date

January 13, 2023

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions

Rheumatoid ArthritisAnkylosing SpondylitisPsoriatic ArthritisPsoriasis

Interventions

DRUG

Remsima IV

Patient will be treated with Remsima IV as per the SmPC or

DRUG

Remsima SC

Patient will be treated with Remsima SC as per the SmPC

Trial Locations (1)

RECRUITING

CHU Purpan Hôpital Pierre Paul Riquet, Toulouse